0001209191-21-054321.txt : 20210901
0001209191-21-054321.hdr.sgml : 20210901
20210901193446
ACCESSION NUMBER: 0001209191-21-054321
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210830
FILED AS OF DATE: 20210901
DATE AS OF CHANGE: 20210901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sepp-Lorenzino Laura
CENTRAL INDEX KEY: 0001777421
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 211231393
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS, INC.
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-30
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001777421
Sepp-Lorenzino Laura
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
0
1
0
0
EVP, Chief Scientific Officer
Common Stock
2021-08-30
4
M
0
27000
13.40
A
29391
D
Common Stock
2021-08-30
4
M
0
70000
14.25
A
99391
D
Common Stock
2021-08-30
4
S
0
15839
152.75
D
83552
D
Common Stock
2021-08-30
4
S
0
20645
153.64
D
62907
D
Common Stock
2021-08-30
4
S
0
28669
154.77
D
34238
D
Common Stock
2021-08-30
4
S
0
16115
155.61
D
18123
D
Common Stock
2021-08-30
4
S
0
7425
156.79
D
10698
D
Common Stock
2021-08-30
4
S
0
3932
157.77
D
6766
D
Common Stock
2021-08-30
4
S
0
1515
158.90
D
5251
D
Common Stock
2021-08-30
4
S
0
2653
159.64
D
2598
D
Common Stock
2021-08-30
4
S
0
207
160.47
D
2391
D
Stock Option (right to buy)
13.40
2021-08-30
4
M
0
27000
0.00
D
2030-03-01
Common Stock
27000
82000
D
Stock Option (right to buy)
14.25
2021-08-30
4
M
0
70000
0.00
D
2029-06-02
Common Stock
70000
80000
D
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.16 to $153.155, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.16 to $154.15, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.22 to $155.215, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.22 to $156.19, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.22 to $157.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.305 to $158.245, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.31 to $159.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.31 to $160.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.40 to $160.53, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 30, 2021.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 84,375 shares as of August 30, 2021.
/s/James Basta, attorney-in-fact
2021-09-01